Expand PVLA Menu
PVLA MENU

PVLA Latest Press Releases

-- January 9, 2026 --

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies Globe Newswire 7:30 AM

-- January 7, 2026 --

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs Globe Newswire 7:30 AM

-- December 16, 2025 --

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas Globe Newswire 7:30 AM

-- December 15, 2025 --

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies Globe Newswire 6:00 AM

-- November 11, 2025 --

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- November 6, 2025 --

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference Globe Newswire 7:30 AM

-- November 5, 2025 --

Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies Globe Newswire 6:00 AM

-- November 4, 2025 --

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 Globe Newswire 7:30 AM

-- October 13, 2025 --

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- September 24, 2025 --

Palvella Therapeutics Announces Expansion of QTORIN Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies Globe Newswire 6:00 AM

-- September 17, 2025 --

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy Globe Newswire 7:30 AM

-- September 15, 2025 --

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous Malformations Globe Newswire 7:30 AM

-- September 3, 2025 --

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer Globe Newswire 7:30 AM

-- August 28, 2025 --

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes